Veradermics, Incorporated reported a net loss of $27.2 million for the three months ended March 31, 2026, as it increased investment in late-stage dermatology programs. Research and development expenses rose to $20.9 million and general and administrative costs reached $8.9 million, reflecting expanded clinical activity and public-company readiness.
The company strengthened its balance sheet with an IPO in February 2026 generating net proceeds of $269.1 million, bringing cash, cash equivalents and marketable securities to $390.8 million as of March 31, 2026. Subsequent May 2026 follow-on and private offerings added $472.0 million in gross proceeds to support development of lead candidate VDPHL01 and its broader dermatology pipeline.
Veradermics, Inc. reported a larger net loss for the first quarter of 2026 as it accelerated late-stage development of its lead hair-loss drug VDPHL01 and strengthened its balance sheet. Net loss was $27.2 million, compared with $12.4 million a year earlier, driven by higher R&D and G&A spending.
Cash, cash equivalents and marketable securities were $390.8 million as of March 31, 2026, reflecting proceeds from an upsized IPO in February. A follow-on offering completed after quarter-end raised an additional $472.0 million in gross proceeds, contributing to an aggregate $766.8 million raised in 2026 and a projected cash runway into 2030.
The company highlighted positive topline results from Part A of Phase 2/3 Study ‘302’ of oral, extended-release minoxidil tablet VDPHL01 in male pattern hair loss, completion of enrollment in confirmatory Phase 3 Study ‘304’, and ongoing enrollment in Phase 2/3 Study ‘306’ in women, positioning VDPHL01 as a potential first-in-class non-hormonal oral treatment.
Veradermics, Incorporated ownership disclosure: Citadel Advisors LLC and related reporting persons report shared beneficial ownership of 1,870,775 shares of Common Stock. The filing states this position represents 4.5% of shares outstanding based on 41,183,254 Shares outstanding as of May 1, 2026.
The joint filing lists the reporting group (Citadel Advisors, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities entities and Kenneth Griffin) and details shared voting and dispositive power over the reported shares. Signature blocks show the statement was filed on behalf of the reporting persons.
Suvretta Capital–related funds filed Amendment No. 1 to their Schedule 13D on Veradermics, Inc., updating their ownership and warrant holdings. Suvretta Capital Management and Aaron Cowen report beneficial ownership of 4,172,121 shares of common stock, representing 9.9% of the class, including 3,151 shares issuable upon exercise of Pre-Funded Warrants.
Averill Master Fund, Ltd. reports 3,650,103 shares, or 8.7% of the class, and Averill Madison Master Fund, Ltd. reports 522,018 shares, or 1.2%. The amendment describes an April 29, 2026 Securities Purchase Agreement under which Averill Master Fund acquired 149,000 Pre-Funded Warrants and Averill Madison Master Fund acquired 151,000, each at $99.99999 per warrant with a $0.00001 exercise price, subject to a Beneficial Ownership Limitation of generally 9.99%, or up to 19.99% upon election.
Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades. On May 1, 2026, reporting persons including Suvretta Capital Management, LLC and Averill funds reported the indirect acquisition of two blocks of Pre-Funded Warrants for 151,000 and 149,000 underlying shares of Veradermics common stock. These transactions are coded as grants or awards, so they increase indirect exposure to Veradermics without reflecting discretionary buying or selling in the open market.
Veradermics, Incorporated received an updated ownership filing from Longitude-affiliated investment funds and their managers. The group reports beneficial ownership of Veradermics common stock through several Delaware entities and two individual managers, reflecting coordinated investment positions.
Longitude Venture Partners V, L.P. and related entities report 2,600,399 shares, or 6.3% of the common stock, while Longitude 103.8 East, L.P. and its affiliates report 2,053,474 shares, or 5.0%. Individually, Patrick G. Enright and Juliet Tammenoms Bakker are each deemed to beneficially own 4,653,873 shares, representing 11.3% of Veradermics’ 41,184,080 shares outstanding. The filing details shared voting and dispositive power across these funds and clarifies that each reporting person generally disclaims beneficial ownership beyond their pecuniary interest.
Seven Fleet Master Fund LP and related entities filed a Schedule 13D on Veradermics, Inc., reporting beneficial ownership of 80,000 common shares, or 0.2% of 41,184,080 shares outstanding. The stake, held through Seven Fleet Master Fund, was acquired mainly in open-market and follow-on offering purchases.
The fund paid an aggregate purchase price of about $8,000,000 for these shares, including 80,000 shares bought at $100.00 per share in the issuer’s follow-on offering on May 1, 2026. The investors state they viewed the stock as undervalued and an attractive opportunity when purchased.
The filing outlines a flexible strategy: the group may buy more shares, sell shares, or engage in hedging, and may communicate with management, the board, other shareholders, or potential acquirers about capital allocation, ownership structure, a possible sale of the company or its parts, and board or operational changes.
Seven Fleet Capital Management LP, as a reporting person for Veradermics, Inc., has filed an initial Form 3 showing indirect ownership of 80,000 shares of common stock held by managed funds. The filing notes that Dr. Brian Liu may be deemed to control the reporting entities and may be deemed to beneficially own these shares, but he disclaims beneficial ownership except to the extent of any indirect pecuniary interest.
Veradermics, Incorporated completed an underwritten public offering of 3,843,790 shares of common stock at $100.00 per share, using its effective Form S-1 registration statements. The underwriters also received a 30-day option to buy up to an additional 576,568 shares at the same public price, less fees.
At the same time, Veradermics closed a private placement of pre-funded warrants to Suvretta Capital–affiliated investors, covering 300,000 shares of common stock at $99.99999 per warrant, for gross proceeds of about $30.0 million before costs. Each pre-funded warrant carries a nominal exercise price of $0.00001 per share, can be exercised in cash or cashlessly, and remains outstanding until fully exercised.
The warrants include a beneficial ownership limitation that blocks exercises above 9.99% of Veradermics’ common stock, with the ability for a holder to adjust the cap up to 19.99% effective on the 61st day after notice. The company agreed to customary covenants in the Securities Purchase Agreement, including restrictions on additional equity issuances for 90 days, subject to exceptions.
Veradermics is offering 3,843,790 shares of common stock at $100.00 per share to raise gross proceeds of $384,379,000. The company concurrently agreed to sell pre-funded warrants in a private placement (PIPE) for 300,000 shares at $99.99999 each to affiliates of Suvretta Capital; those pre-funded warrants are immediately exercisable, subject to ownership limits. Net proceeds from the offering and PIPE are estimated at approximately $388.8 million (or $443.0 million if the underwriters’ option is fully exercised), which the company intends to use for commercial launch activities, manufacturing expansion, clinical development and general corporate purposes.